再生元制药公司(REGN)今日盘前股价大涨5.69%，引发市场广泛关注。
消息面上，再生元制药在盘前公布了第二季度财报，业绩大幅超出市场预期。数据显示，公司Q2营收达到42.91亿美元，显著高于市场预期的38.16亿美元；调整后每股收益为14.29美元，远超分析师预期的10.3美元。这一强劲表现主要得益于公司核心产品的持续增长。
与此同时，合作伙伴赛诺菲也公布了亮眼的业绩，其与再生元共同开发的明星药物Dupixent（杜皮森特）第二季度销售额按固定汇率计算增长38%，达到51.5亿欧元，远超市场预期。赛诺菲还因此上调了全年销售预期，这些利好消息共同推动了再生元制药股价在盘前大幅走高。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.